Lifeon Pharmaceutical: Received the Clinical Trial Approval Notice for Drugs

Lifeon Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" for Beipaidu Acid Tablets issued by the National Medical Products Administration. Beipaidu Acid Tablets are an adenosine triphosphate-citrate lyase inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver. The original research drug was approved for marketing in the United States in 2020 and has not yet been launched domestically. This registration application is classified as a Class 3 chemical drug. According to data from the Drug Evaluation Center of the National Medical Products Administration, the company is the third domestic enterprise approved for clinical trials. The approval of the clinical trial application for Beipaidu Acid Tablets will not have a significant impact on the company's short-term performance